End of Phase 2 Services
One of the primary reasons a company does not get first-cycle approval of its drug is poor communication with the FDA. ECG helps companies improve that communication by focusing not only on frequency and timing of communication but on the data and content it presents.
End of Phase 2 is a milestone in the lifecycle of a drug's development and presents a variety of important communication opportunities. ECG has the experience and expertise to help your team plan and implement for success as you approach this milestone.
We can work with you to prepare targeted communication for your End of Phase 2 Meeting, one that will set up a Phase 3 program with a better likelihood for approval, one that makes the best use of your data for your intended product profile and addresses issues before they become obstacles.
We can help you prepare messages and materials for other important communication opportunities: raising capital, establishing potential partnerships and collaborations, IPOs, and even the marketing of a product or a company. Documents that are message-driven and issue-oriented along with well-designed and well-rehearsed presentations help you make the most of opportunities to advocate for your data and its potential.
The ECG consultant team can help you with:
- Messaging
- Preparation of thorough Q & A Books
- End of Phase 2 Advisory Board Meetings
- Developing scientific context for clinical development plans
- Creating and delivering powerful presentations
- Helping clear obstacles by preparing targeted responses to regulatory queries
- Coaching your team's speakers and Q & A responders
|
